<DOC>
	<DOCNO>NCT00985426</DOCNO>
	<brief_summary>The purpose study explore safety immunogenicity new investigational hepatitis B virus vaccine , HEPLISAV™ , patient 18 75 year age progressive loss kidney function .</brief_summary>
	<brief_title>Immunogenicity Safety HEPLISAV™ Hepatitis B Virus Vaccine Chronic Kidney Disease ( CKD ) Patients</brief_title>
	<detailed_description>The purpose study explore safety Immunogenicity new investigational hepatitis B virus vaccine , HEPLISAV™ , patient 18 75 year age progressive loss kidney function .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 75 year age ; progressive loss renal function define glomerular filtration rate ( GFR ) ≤ 45 mL/min/1.73 m² ; clinically stable opinion investigator ; serum negative HBsAg , antiHBsAg , antibody hepatitis B core antigen ( HBcAg ) , Hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) ; woman childbearing potential , agree consistently use highly effective method birth control screen visit treatment phase 28 day last injection ; schedule undergo kidney transplant next 12 month ; able willing provide inform consent . female , pregnant , breastfeeding , plan pregnancy ; history consider investigator high risk recent exposure HBV , HCV , HIV ; example , current intravenous drug use , unprotected sex know HBV/HIV positive partner ; know history autoimmune disease ; previously receive HBV vaccine ; history sensitivity component study vaccine ; current illness renal disease substance alcohol abuse opinion investigator would interfere compliance interpretation study result ; undergo chemotherapy expect receive chemotherapy study period ; diagnosis cancer within last 5 year squamous basal cell carcinoma skin ; uncontrolled diabetes hypertension ; unwilling unable comply requirement protocol ; receive blood product immunoglobulin within 3 month prior study entry , likely require infusion blood product study period ; receive follow prior first injection : 3 day : erythropoietin ( exclusionary window apply subject dialysis ) 7 day : intravenous iron 21 day : inactivated virus vaccine 28 day : live virus vaccine systemic corticosteroid ( 3 consecutive day ) immunomodulators immune suppressive medication , exception inhale steroid granulocyte granulocytemacrophage colonysimulating factor ( G/GMCSF ) , investigational medicinal agent At time : injection deoxyribonucleic acid plasmid oligonucleotide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>kidney failure</keyword>
	<keyword>kidney failure , chronic</keyword>
	<keyword>chronic kidney failure</keyword>
	<keyword>hepatitis B virus ( HBV ) vaccine</keyword>
	<keyword>hepatitis B vaccine</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>hepatitis</keyword>
	<keyword>HBV</keyword>
	<keyword>prevention control</keyword>
	<keyword>dialysis</keyword>
</DOC>